Improving clinical trial outcomes in amyotrophic lateral sclerosis | Nature Reviews Neurology
M. Khurram Afzal MD on Twitter: "AEGIS-II Trial European Investigator Meeting #aegis2trial Not all that complicated! @CMichaelGibson https://t.co/cDkBXs0gHS" / Twitter
Research & Innovation on Twitter: "PI Kelvin Lee and research nurse @clhyland_hewitt attending the AEGIS-II investigator meeting to prepare for study set up #aegis2trial @ULHT_News @Johnsonward3 @ULHTHeartCentre @susiebutler20 @NIHRCRNEastMids https ...
CMSJ :: CardioMetabolic Syndrome Journal
CSL Behring on Twitter: "Today, the study design for our landmark Phase 3 AEGIS-II trial was published in @AmericanHeartJ Read more about our cardiovascular research program involving #heartattack survivors: https://t.co/WByn9r3ny6 @CMichaelGibson ...
MemorialCare Heart & Vascular Institute Participating in Global Study of CSL112 in Patients with Acute Coronary Syndrome (AEGIS-II)
CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
Update on HDL Infusions and Atherosclerosis Regression in
Apostolos Dimos MD, MSc - AEGIS-II Trial (NCT03473223) Sub-Investigator - General University Hospital of Larissa | LinkedIn
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH ...
Update on HDL Infusions and Atherosclerosis Regression in
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel | Journal of the American College of Cardiology
AEGIS II | Valley Health System
MegaTrials (> 5,000 patients) - DCRI
CSL Confirms Phase 3 Clinical Trial of New Therapy for Heart Attack Survivors
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II ( AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo- controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after
![PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5ada797ec2f0c65e74ae75f162e1fcc1ce4a86d4/4-Figure1-1.png "PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar")
PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar
.jpg "CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors"){kind=logo}
CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
2019 Annual Report: Reducing Risk, Changing Paradigms - DCRI
![PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5ada797ec2f0c65e74ae75f162e1fcc1ce4a86d4/6-Figure3-1.png "PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar")
PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome | JACC: Heart Failure
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? - Annals of Oncology
CSL to start Phase lll trial of CSL112 for heart attack survivors - Clinical Trials Arena
![figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram](https://www.researchgate.net/publication/346206981/figure/fig2/AS:961661917741057@1606289476103/figures-fig1Study-design-and-timelineFMC-first-medical-contact.jpg "figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram")
figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram
